Biotech Omeros Corporation (NASDAQ: OMER ) has been on a tear since the start of September. With momentum building from a product headed for a Food and Drug Administration review and analyst upgrades, shares are up almost 16% today and have more than doubled in the last month.
In the following video, from The Motley Fool's health-care show Market Checkup, analyst Max Macaluso discusses the market's enthusiasm about Omeros and the opportunities and risks investors should watch for.
Investing in biotechs
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.
Note: This video was recorded on Oct. 2, 2013.